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Oxyphil or Hu ¨rthle cell tumours of the thyroid are characterised by their consistent excessive number of mitochondria. A recently
discovered gene, GRIM-19 has been found to fulfil two roles within the cell: as a member of the interferon-b and retinoic acid-induced
pathway of cell death, and as part of the mitochondrial Complex I assembly. In addition, a gene predisposing to thyroid tumours with
cell oxyphilia (TCO) has been mapped to chromosome 19p13.2 in one family. A cluster of genes involved in mitochondrial
metabolism occurs in this region; one of these is GRIM-19. We have searched for GRIM-19 mutations in a series of 52 thyroid
tumours. Somatic missense mutations in GRIM-19 were detected in three of 20 sporadic Hu ¨rthle cell carcinomas. A germline
mutation was detected in a Hu ¨rthle cell papillary carcinoma arising in a thyroid with multiple Hu ¨rthle cell nodules. No mutations were
detected in any of the 20 non-Hu ¨rthle cell carcinomas tested, nor in any of 96 blood donor samples. In one of the sporadic Hu ¨rthle
cell papillary carcinomas positive for GRIM-19 mutation, we have also detected a ret/PTC-1 rearrangement. No GRIM-19 mutations
were detected in any of the six cases of known familial Hu ¨rthle cell tumour tested, so that our results do not support the
identification of GRIM-19 as the TCO gene. The GRIM-19 mutations we have detected are the first nuclear gene mutations specific to
Hu ¨rthle cell tumours to be reported to date; we propose that such mutations can be involved in the genesis of sporadic or familial
Hu ¨rthle cell tumours through the dual function of GRIM-19 in mitochondrial metabolism and cell death.
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Oxyphil or Hu ¨rthle cell thyroid tumours constitute an unusual
form of neoplasm composed of cells with a great increase in
mitochondrial number, corresponding morphologically to their
voluminous, granular, eosinophilic cytoplasm (Hamperl, 1962;
Nesland et al, 1985; Sobrinho-Simo ˜es et al, 1985; Rosai et al, 1992;
Sobrinho-Simo ˜es, 1995). The excessive numbers of mitochondria
are found in all tumour cells, both in adenomas and in carcinomas.
Large deletions of mitochondrial DNA (mtDNA), as well as
somatic mutations of some mitochondrial genes are the hallmark
of Hu ¨rthle cell tumours (Ma ´ximo and Sobrinho-Simo ˜es, 2000a;
Ma ´ximo et al, 2002). Hu ¨rthle cell tumours are multiple in a
proportion of cases; the multiple tumours more often occur in
younger patients than the solitary tumours, suggesting a germline
defect (Katoh et al, 1998). Dominant inheritance has only rarely
been reported; a study of one pedigree with familial Hu ¨rthle cell
tumours found a linkage to chromosome 19p13.2, but the identity
and function of this TCO gene remains unknown (Canzian et al,
1998).
Recently, a novel gene, GRIM-19, has been identified. It is one of
several genes associated with retinoid-interferon-induced mortality
(GRIM) that have been reported in the literature (Hofmann et al,
1998). GRIM-19 is a cell death regulatory gene that promotes
apoptosis, is a negative regulator of cell growth and is also
involved in mitochondrial metabolism (Angell et al, 2000; Lufei
et al, 2003), it has been mapped to human chromosome 19p13.2
(Chidambaram et al, 2000). GRIM-19 is the human homologue of
the bovine subunit of the mitochondrial NADH:ubiquinone
oxireductase complex (Complex I) of the mitochondrial respira-
tory chain (MRC) (Fearnley et al, 2001). Like cytochrome c, which
has a role in the induction of the cell’s apoptotic programme and
in the MRC (Liu et al, 1996), and endonuclease G, which is released
from mitochondria during apoptosis and subsequently translo-
cated to the nucleus (Li et al, 2001), GRIM-19 has been found to
fulfil two roles within the cell: as a member of the interferon-b and
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sretinoic acid-induced pathway of cell death (Angell et al, 2000),
and as part of the mitochondrial Complex I assembly (Fearnley
et al, 2001). These two seemingly disparate functions may be
linked, through the involvement of mitochondria in apoptotic cell
death.
The functional importance of GRIM-19 has been recently
highlighted by knockout experiments. Huang et al (2004)
generated mice deficient in GRIM-19 by gene targeting, and
showed that homologous deletion of GRIM-19 causes embryonic
lethality at embryonic day 9.5. Interestingly, GRIM-19
 /  blastocysts
display abnormal mitochondrial structure, morphology and
cellular distribution (Huang et al, 2004).
The consistent linkage of increased mitochondrial number and
increased cell growth that characterises Hu ¨rthle cell tumours
suggests that one gene could be involved in both features. The dual
role of GRIM-19 in apoptosis and mitochondrial biogenesis makes
it a good candidate for being a gene involved in Hu ¨rthle cell
tumorigenesis. Its localisation to the same region as the TCO gene
(chromosome 19p13.2) also suggested that it could be involved
in the aetiopathogenesis of familial Hu ¨rthle cell tumours. We have
therefore searched for GRIM-19 mutations in Hu ¨rthle cell tumours,
and in controls.
Lufei et al (2003) and Zhang et al (2003) have demonstrated that
the major role of GRIM-19 in control of cell growth is exerted
through STAT3, a transcription factor known to be inhibited by
GRIM-19 binding (Lufei et al, 2003; Zhang et al, 2003). Signal
transducers and activators of transcription (STATs) are a family of
latent cytoplasmic transcription factors that are activated after
recruitment by the cytokine membrane receptors and subsequent
phosphorylation. STAT proteins form homo- or heterodimers by
reciprocal interactions between SH2 domains and phosphorylated
tyrosine residues, translocate to the nucleus, bind to DNA and
regulate their target gene expression (Darnell et al, 1994). It was
suggested that activation of STAT3 may contribute to the loss
of cell growth control, therefore leading to carcinogenesis (Grandis
et al, 2000), by inducing elevated expression of genes involved in
controlling fundamental cellular processes such as cyclin D1
(Fukada et al, 1998), c-Myc (Bromberg et al, 1999), p21
WAF1/CIP1
(Chin et al, 1996), as well as VEGF (Niu et al, 2002) and ICAM1
(Caldenhoven et al, 1996; Cantwell et al, 1998; Hwang et al, 2003).
Owing to the difficulty in studying the functional impairment
of mutated GRIM-19 directly in formalin-fixed tissue, we have
investigated the levels of expression of ICAM1 in our series in an
attempt to provide indirect evidence of the putative loss of
function of GRIM-19.
Since ret/PTC rearrangements and B-RAF mutations are
particularly prevalent in papillary carcinomas regardless of
whether or not they have Hu ¨rthle cell features (Grieco et al,
1990; Soares et al, 1998, 2003; Sugg et al, 1998; Cohen et al, 2003;
Kimura et al, 2003), we have also searched for the aforementioned
genetic alterations in Hu ¨rthle cell carcinomas with GRIM-19
mutations.
MATERIALS AND METHODS
Material
We studied 26 sporadic Hu ¨rthle cell tumours (five adenomas, 11
cases of the Hu ¨rthle cell variant of follicular carcinoma and 10
cases of the Hu ¨rthle cell variant of papillary carcinoma, all showing
papillary carcinoma nuclear features), six carcinomas from two
families with Hu ¨rthle cell tumours, 20 cases of non-Hu ¨rthle cell
carcinomas (10 follicular carcinomas and 10 papillary carcinomas)
(DeLellis et al, 2004) and 96 blood donor samples. In one of the
families (four cases) there was known linkage to chromosome
19p13.2. The study was approved by the Ethical Committees of all
Institutions involved and informed consent was obtained from all
individuals studied.
DNA extraction
DNA was extracted from microdissected frozen and/or paraffin-
embedded tissue pairs (tumour and adjacent ‘normal’ thyroid)
using the NucleoSpin
s Tissue Kit (Macherey-Nagel, Du ¨ren,
Germany). DNA from blood of some patients and from blood
donor samples was also extracted using the same procedure.
Screening of GRIM-19 mutations
We searched for mutations in all five exons of GRIM-19 including
intronic boundaries (primer sequences shown in Table 1) using
PCR/Automated sequencing. All PCR amplifications were per-
formed in a 25ml volume containing 200mM of each dNTP,
12.5pmol of each of the forward and reverse primers, 50mM KCl,
10mM Tris-HCl (pH 9.0), 1.5mM MgCl2 and 1U of Taq DNA
polymerase (Amersham Pharmacia Biotech). Cycling conditions
were a single predenaturation step at 941C for 5min followed by
35 cycles of denaturation at 941C for 20s, annealing at 601C for
20s and elongation at 721C for 30s, and a final incubation at 721C
for 5min. PCR products were separated by electrophoresis on
2% agarose gels and purified using the NucleoSpin
s Extract Kit
(Macherey-Nagel, Du ¨ren, Germany). Sequencing analysis was then
carried out on purified products using the ABI Prism BigDyet
Terminator Ready Reaction Kit (Perkin-Elmer, Foster City, CA,
USA) and an ABI prism 377 DNA sequencer (Perkin-Elmer). Both
strands were screened using the original primers. All altered
samples were subjected to an additional complete analysis.
Loss of heterozygosity analysis
Two markers (D19S916 and D19S413) located in the TCO (19p13.2)
region were used for the loss of heterozygosity (LOH) studies with
[
32P]dCTP (Amersham, UK) radioactive PCR amplification.
Cycling conditions were a single predenaturation step at 941C for
5min followed by 35 cycles of denaturation at 941C for 20s,
annealing at 581C for 20s and elongation at 721C for 30s, and a
final incubation at 721C for 5min. Amplicons were separated on
6% polyacrylamide denaturing gels, and exposed to X-ray film at
room temperature. Loss of heterozygosity was determined by
comparing the intensity of the alleles in heterozygosity samples of
matched tumour and normal DNA. Loss of heterozygosity analysis
was performed in all cases of sporadic (n¼26) Hu ¨rthle cell
tumours.
Table 1 Primer sequences used in GRIM-19 amplification and sequen-
cing
Primer sequence (50-30)
a
Exon-1 GCA ACA CCC CAG AGG CAA GGT GA
AGA CTC TGA GAC CCC GGC GCA
Exon-2 CAG TGT CCC CTG ATT GCA GAC
ACT TTC AGA CAA CGC CCA CCA
Exon-3 GGT CTG ACC TGA GTG TGG GTT
CTT CCG GCC AGT GAC CTC CCA
Exon-4 AGG CTT GAA GGG GTG CTA CTA
TCT GCC GTG GCT GGC ACC TCT
Exon-5 GGT GGC TGT GCC TCT ACC CAT
AAA GGG GGT CAG GGG TCC TTT
aFor each exon, the first oligonucleotide represents the forward primer, and the
second corresponds to the reverse primer.
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To obtain an indirect evaluation of the functional activity of
GRIM-19, we calculated the relative expression of ICAM1 (tumour
tissue vs normal adjacent tissue) in 26 Hu ¨rthle cell tumours with
and without GRIM-19 mutations. ICAM1 is known to be
upregulated by STAT3, a transcription factor whose function is
inhibited by GRIM-19 protein (Lufei et al, 2003; Zhang et al, 2003).
ICAM1 expression was performed as follows. For each sample
1.0mg of RNA was reverse transcribed in a reaction volume of 20ml
in the presence of 4mM dNTP, 1.0Uml
 1 RNase inhibitor, 2.5mM
random primer P (dN)6 and 10Uml
 1 M-MLV reverse transcrip-
tase. Reverse-transcribed cDNAs (0.25mg) from normal and
neoplastic tissues were used to coamplify the housekeeping gene
– glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (primers
GAPDHF – tgt cag tgg tgg gac ctg acc t – and GAPDHR – cac cct gtt
gct gta gcc aaa tt; amplicon: 254bp), and the differentially
expressed gene – ICAM1 gene (primers ICAM1F – caa ccg gaa
ggt gta tga act ga – and ICAM1R – tgg cag cgt agg gta agg ttc tt;
amplicon: 186bp). Cycling conditions were a single predenatura-
tion step at 941C for 5min followed by 24 cycles of denaturation at
941C for 20s, annealing at 581C for 20s and elongation at 721C for
20s, and a final incubation at 721C for 5min. The PCR products
were separated in an agarose gel (2%), and stained with ethidium
bromide. The intensity of the fluorescence was automatically
measured and integrated using the Multi-Analyst – version 1.1 –
software in the BIO RAD Gel DOC 1000 (BIO RAD, CA, USA). All
the quantitations were performed in triplicate.
Screening of ret/PTC rearrangements
RNA extracted from paraffin-embedded tumour tissue of patients
who presented GRIM-19 mutations was used for detecting ret/PTC
rearrangements following the procedures previously described
(Finn et al, 2003).
Screening of B-RAF mutations
To screen for B-RAF mutations, we analysed DNA extracted from
paraffin-embedded tumour tissue and adjacent thyroid tissue of
patients who presented GRIM-19 mutations following the proce-
dures previously described (Davies et al, 2002; Soares et al, 2003).
Statistical analysis
The statistical analysis of the results was performed using w
2 test
with the Yates correction, Fisher’s exact test and Student’s t-test. A
P-value of o0.05 was considered statistically significant.
RESULTS
Screening of GRIM-19 mutations
The results of GRIM-19 analysis are summarized in Table 2 and
Figure 1. Sequence determination of the five exons of GRIM-19 in
the 26 apparently sporadic Hu ¨rthle cell tumours disclosed the
existence of four mutations: a C-T substitution at nucleotide 77
(exon 1) resulting in an alanine-to-valine change at residue 26 in
patient 4 (Hu ¨rthle cell variant of follicular carcinoma); a G-C
substitution at nucleotide 264 resulting in a lysine-to-asparagine
change at residue 88 (exon 1) in patient 5 (Hu ¨rthle cell variant of
papillary carcinoma with Warthin’s like features) (Figure 1); an
A-G substitution at nucleotide 247 resulting in a serine-to-
glycine change at residue 83 (exon 1) in patient 6 (Hu ¨rthle cell
variant of papillary carcinoma); and a G-C substitution at
nucleotide 593 resulting in a arginine-to-proline change at residue
198 (exon 5) in patient 7 (Hu ¨rthle cell variant of papillary
carcinoma). All mutations detected were heterozygous.
In patient 5, the thyroid tissue apart from the papillary
carcinoma was almost totally occupied by several nodules
composed of Hu ¨rthle cells; in all samples tested, including the
carcinoma, one benign nodule and the internodular normal tissue,
we detected the same mutation (a G-C substitution at nucleotide
264 resulting in a lysine-to-asparagine change at residue 88). The
same mutation was also detected in the peripheral blood of the
patient thus confirming its germline nature. The germline nature
of the mutation was confirmed by its detection in the peripheral
blood of one son, aged 41 years, with no clinical or ecographic
signs of thyroid disease. The mutation was not detected in the
other son nor in the daughter of the patient. No mutations were
detected in the adjacent normal thyroid parenchyma of the other
three cases with a GRIM-19 mutation (patients 4, 6 and 7), nor in
any of the 42 other normal thyroid samples.
We did not detect mutations in the GRIM-19 gene in any of the
six cases of known familial Hu ¨rthle cell tumours, in any of the 20
cases of non-Hu ¨rthle follicular and papillary carcinomas, nor in
any of the 96 blood donor samples. The frequency of GRIM-19
somatic mutations in the cases of Hu ¨rthle cell variant of follicular
carcinoma (one out of 11; 9.1%) is not statistically different
from the frequency of GRIM-19 somatic mutations in cases of
Hu ¨rthle cell variant of papillary carcinoma (two out of 10;
20.0%) (P¼0.476); the same holds true if the case presenting the
GRIM-19 germline mutation is included (three out of 10;
30.0%) (P¼0.223). None of the previously described polymor-
phisms (National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov)) occurring at exonic regions were detected
in these cases.
The presence of GRIM-19 mutations was not significantly
associated with the age and/or gender of the patients (data not
shown) nor with the histotype of the lesions other than the
oxyphilia (Figure 2), including the presence or absence of
lymphocytic thyroiditis. No significant association was also found
between the presence of GRIM-19 mutations and the mtDNA
somatic mutations detected in a previous study (Ma ´ximo et al,
2002) (data not shown).
Loss of heterozygosity
The 26 cases in which LOH analysis was performed were
informative for at least one of the two markers. We did not find
LOH in any of the four Hu ¨rthle cell tumours presenting GRIM-19
mutations, nor in any of the other 22 sporadic Hu ¨rthle cell
tumours.
Expression of ICAM1
The results are summarized in Table 3. The four tumours with
mutations had significantly (Po0.001) higher levels of ICAM1
expression in tumoural tissue vs normal tissue (range of the ratio
between the expressions of ICAM1 in tumoural tissues vs normal
tissue: 3.2–5.0; mean7standard deviation¼3.970.8) (Table 3)
than the 22 cases without GRIM-19 mutation (range: 0.9–2.4;
mean7standard deviation¼1.470.4). Only two cases without
Table 2 Summary of the data on the four cases with GRIM-19 mutations
Case
Age
(years) Diagnosis
Nucleotide
alteration
Protein
alteration
4 42 HCFC C77T A26V
5 60 HCPC G264C K88N
6 33 HCPC A247G S83G
7 32 HCPC G593C R198P
HCFC¼Hu ¨rthle cell variant of follicular carcinoma, HCPC¼Hu ¨rthle cell variant of
papillary carcinoma.
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level of expression in tumoural tissue higher than 2 (2.3 and 2.4,
respectively).
Screening for RET/PTC rearrangements and B-RAF
mutations
The data concerning the screening for RET/PTC rearrangements
and B-RAF mutations in cases displaying GRIM-19 mutation are
summarized in Table 4 (case 6 – not studied for technical
limitations). Ret/PTC-1 chimeric transcripts were detected in one
case (Case 7); no ret/PTC-3 chimeric transcripts were detected in
any case. No mutations in exons 11 and 15 of B-RAF were detected
in any of the three cases from which material was available.
DISCUSSION
The GRIM-19 mutations we have described are the first nuclear
gene mutations specific to Hu ¨rthle cell tumours to be reported to
date. The detection of GRIM-19 mutations in four of 26 apparently
sporadic Hu ¨rthle cell tumours, and their absence in 20 non-
Hu ¨rthle cell tumours and 96 blood donors support the hypothesis
that alterations of GRIM-19 are involved in the etiopathogenesis of
these tumours. Further support comes from a search for germline
mutations. While these were not found in the two known families
studied, one germline mutation was found in the 142 samples
tested (46 normal thyroids and 96 blood donor samples), and this
occurred in the only apparently sporadic tumour with multiple
Hu ¨rthle cell lesions. None of the alterations detected were
previously described as polymorphisms, suggesting that might
affect the function of the protein, or that they are rare
polymorphisms. When we compare the amino-acid sequence of
the protein GRIM-19 of four different species (Homo sapiens, Bos
taurus, Mus musculus and Xenopus tropicalis), two of the
mutations are located in phylogenetically conserved positions
(K88N, case 5 and R198P, case 7) (Figure 3), suggesting that they
might directly affect the function of the protein. The remaining
mutations (A26V, case 4 and S83G, case 6) are located in a region
of human GRIM-19 protein that has no correspondence to the
Figure 1 Electropherograms showing GRIM-19 mutations in case 4 (A – mutated sequence, B – wild-type sequence), case 5 (C – mutated sequence, D
– wild-type sequence), case 6 (E – mutated sequence, F – wild-type sequence) and case 7 (G – mutated sequence, H – wild-type sequence). The mutated
nucleotides are indicated by the arrow. For details see Table 2.
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four.
In contrast to the absence of other documented nuclear genetic
alterations, several mtDNA alterations (including large deletions
and somatic mutations) have been described in sporadic Hu ¨rthle
cell tumours (Tallini et al, 1994; Ma ´ximo and Sobrinho-Simo ˜es,
2000b; Ma ´ximo et al, 2002). Curiously, most of the somatic
mutations of the mtDNA on record involve genes that, like GRIM-
19, code for components of Complex I of MRC (Yeh et al, 2000;
Ma ´ximo et al, 2002). These genes are crucial for the oxidative
phosphorylation process and consequently for the cell’s energy
production, and it has been suggested that mutations in genes
directly or indirectly affecting mitochondrial function could be the
cause of the increase in mitochondrial number in Hu ¨rthle cell
tumours (Katoh et al, 1998). It is known that a defect in the energy
production machinery of the cell can lead to a secondary increase
in the number of mitochondria, through a feedback mechanism
(Attardi et al, 1995). Loss of function of GRIM-19 can therefore
explain the mitochondrial excess typical of Hu ¨rthle cell tumours.
Mutations in GRIM-19 as well as affecting mitochondrial
number could also influence cell growth and apoptosis. This role
of GRIM-19 was demonstrated using in vitro models by Angell et al
(2000), who showed that overexpression of GRIM-19 enhanced cell
death in MCF-7 cells, whereas its downregulation, as well as its
deletion, provided growth advantage and decreased cell death
(Angell et al, 2000). Huang et al (2004) confirmed that GRIM-19
protein cellular localisation in various cell types is primarily
mitochondrial. Furthermore, GRIM-19 is detected in the native
form of mitochondrial complex I and the elimination of GRIM-19
destroys the assembly and electron transfer activity of Complex I
and also influences the other complexes in the mitochondrial
respiratory chain (Huang et al, 2004).
In this study, GRIM-19 mutations were found in 16% of Hu ¨rthle
cell tumours. However GRIM-19 is one of a number of genes that
code for proteins involved in mitochondrial electron transport.
Clusters of these genes occur at 19p13.2 (http://www.ncbi.nlm.
nih.gov) and at 17p13 (Farrand et al, 2002), both regions of the
genome linked to Hu ¨rthle cell tumours. It is therefore likely that
mutations in other genes with similar functions are involved in the
causation of Hu ¨rthle cell tumours of the thyroid, and they should
also be considered candidate genes for mitochondrial-rich
tumours of other sites.
AB
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Figure 2 Histology of GRIM-19 mutated tumours. A and B –H u ¨rthle
cell lesions from case 5 presenting GRIM-19 germline mutations (A –
Hu ¨rthle cell adenoma; B –H u ¨rthle cell variant of papillary carcinoma). (C)
Hu ¨rthle cell variant of follicular carcinoma (case 4) displaying somatic
GRIM-19 mutation. (D)H u ¨rthle cell variant of papillary carcinoma (case 7)
presenting a somatic GRIM-19 mutation and a ret/PTC-1 rearrangement.
Table 3 Summary of the data on ICAM1 relative expression in the four
cases with GRIM-19 mutations
Case Age (years) Diagnosis
ICAM1 expression
a
Tumour tissue vs
normal tissue
4 42 HCFC 3.270.4
5 60 HCPC 4.170.1
6 33 HCPC 3.370.3
7 32 HCPC 5.070.3
HCFC¼Hu ¨rthle cell variant of follicular carcinoma, HCPC¼Hu ¨rthle cell variant of
papillary carcinoma.
aValues are expressed as the ratio between the expressions of
ICAM1 in tumoural tissues vs normal tissue, in mean7s.d. (after three measurements
per case).
Table 4 Summary of the data regarding ret/PTC rearrangements and
B-RAF mutations in the four patients with GRIM-19 mutations
Case Age (years) Diagnosis
B-RAF
mutation
RET/PTC
rearrangements
4 42 HCFC Negative Negative
5 60 HCPC Negative Negative
6 33 HCPC Not done Not done
7 32 HCPC Negative Positive
HCFC¼Hu ¨rthle cell variant of follicular carcinoma, HCPC¼Hu ¨rthle cell variant of
papillary carcinoma.
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Figure 3 Alignment of the GRIM-19 protein sequence in four species (Homo sapiens, Bos taurus, Mus musculus and Xenopus tropicalis; accession number:
NP_057049, NP_788845, NP_075801 and NP_988900, respectively). Arrows indicate the positions of the amino acids mutated in our series of Hu ¨rthle cell
tumours (see Table 2).
GRIM-19 mutations in Hu ¨rthle cell tumours
VM a ´ximo et al
1896
British Journal of Cancer (2005) 92(10), 1892–1898 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sThe major role of GRIM-19 in control of cell growth is exerted
through STAT3, a transcription factor known to be inhibited by
GRIM-19 binding (Lufei et al, 2003; Zhang et al, 2003). We have
shown that the cases with GRIM-19 mutations display increased
expression of the STAT3 regulated gene ICAM1; this finding fits
with a loss of function of GRIM-19. Only two of the 22 cases
without mutation in GRIM-19 gene showed a slightly elevated
expression of the ICAM1 gene: the levels in these two cases were
considerably lower (P¼0.07) than those detected in four cases
with mutations and may reflect alterations in pathways other than
STAT3 pathway.
The failure to detect LOH with the limited range of markers used
does not exclude a tumorigenic role for GRIM19 mutations. Angell
et al (2000) showed that downregulation of GRIM-19 was able to
provide growth advantage, and cooperating mutations in one of
the many other nuclear or mitochondrial genes with similar
functions could also be important in this setting.
Ret/PTC rearrangements were initially reported to be restricted
to conventional papillary thyroid carcinomas (Grieco et al, 1990).
Later, Cheung et al (2000) demonstrated that ret/PTC rearrange-
ments could also be detected in cases of Hu ¨rthle cell variant of
papillary carcinoma, thus supporting the assumption that ret/PTC
is specific for the papillary phenotype (Cheung et al, 2000; DeLellis
et al, 2004). Chiappetta et al (2002) reported the presence of the
rearrangement in both benign and malignant Hu ¨rthle thyroid
tumours including follicular and papillary histotypes; this finding
remains to be confirmed in other series. B-RAF mutations have
also been frequently detected in cases of Hu ¨rthle cell variant of
papillary carcinoma (Trovisco et al, 2004), but not in other types
of Hu ¨rthle cell tumour (Kimura et al, 2003; Soares et al, 2003). In
order to verify if the GRIM-19 mutation may cooperate with those
genetic events in Hu ¨rthle cell tumours, we have searched for them
in GRIM-19-positive cases. The detection of a ret/PTC-1 rearran-
gement in Case 7 (Hu ¨rthle cell variant of papillary carcinoma)
suggests that GRIM-19 mutation may serve as a predisposing
alteration for the occurrence of tumours with cell oxyphilia. Other
alterations, such as ret/PTC rearrangement or B-RAF mutation,
may be necessary for the acquisition of the malignant phenotype,
as in non-Hu ¨rthle cell papillary carcinomas (Grieco et al, 1990;
Soares et al, 1998, 2003; Sugg et al, 1998; Cohen et al, 2003; Kimura
et al, 2003).
The autosomal dominant inheritance of Hu ¨rthle cell tumours
has been described in a single family (Canzian et al, 1998). A
separate study of a large number of thyroidectomies for Hu ¨rthle
cell tumours found that about 20% of cases showed multiple
separate Hu ¨rthle cell tumours, and that these were significantly
younger and much more often female than the solitary tumours
(Katoh et al, 1998). No mutations were detected in any of the five
exons, nor in the respective intronic boundaries of GRIM-19 in the
six cases from two Hu ¨rthle cell tumour families. Since four of these
cases belonged to the family described by Canzian et al (1998), our
results do not support the identification of GRIM-19 as the TCO
gene mapped to chromosome 19p13.2 by those authors (Canzian
et al, 1998).
The observation that the only germline mutation in GRIM-19
found in well over 100 samples tested was in the one patient with
multiple Hu ¨rthle cell tumours suggests that this gene could
account for some cases with a low penetrance pattern of
inheritance. The absence of identifiable lesions in the patient’s
son who also carried the mutated gene is not surprising in view of
his younger age (41 vs 60 years) and the rarity of multiple Hu ¨rthle
cell tumours in males (Katoh et al, 1998).
Proof that a particular mutation is oncogenic requires both the
demonstration of its presence in tumours, and the demonstration
that the mutated gene confers an oncogenic advantage. We have
shown that mutations in GRIM-19 are associated with a specific
subtype of thyroid tumours, and each of the four mutations we
found led to amino-acid substitutions. Downregulation of GRIM-
19 has been shown to confer a growth advantage on cells and to
reduce the likelihood that they will enter apoptosis (Angell et al,
2000). We therefore believe that GRIM-19 mutations can make a
significant contribution to the tumorigenic process in Hu ¨rthle cell
tumours of the thyroid. Further in vitro studies are needed to
demonstrate directly that the mutations we have found lead to
downregulation of GRIM-19 function.
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